All Cycles | |||||||
---|---|---|---|---|---|---|---|
Name | NC/NA | 1 | 2 | 3 | 4 | 5 | All grades |
Injection site reaction | 0% | 40% | 60% | 0% | 0% | 0% | 100% |
Fatigue | 40% | 50% | 10% | 0% | 0% | 0% | 60% |
Chills | 50% | 50% | 0% | 0% | 0% | 0% | 50% |
Fever | 60% | 20% | 20% | 0% | 0% | 0% | 40% |
Headache | 70% | 20% | 10% | 0% | 0% | 0% | 30% |
Abdominal soft tissue necrosis | 90% | 10% | 0% | 0% | 0% | 0% | 10% |
Rash maculo‐papular | 90% | 10% | 0% | 0% | 0% | 0% | 10% |
Depressed level of consciousness | 90% | 0% | 0% | 10% | 0% | 0% | 10% |
Testicular pain | 90% | 10% | 0% | 0% | 0% | 0% | 10% |
Pleural effusion | 90% | 0% | 10% | 0% | 0% | 0% | 10% |
Weight gain | 90% | 10% | 0% | 0% | 0% | 0% | 10% |
Localized edema | 90% | 0% | 10% | 0% | 0% | 0% | 10% |
Myalgia | 80% | 10% | 10% | 0% | 0% | 0% | 20% |
Edema limbs | 80% | 10% | 10% | 0% | 0% | 0% | 20% |
Edema trunk | 90% | 10% | 0% | 0% | 0% | 0% | 10% |
Cough | 90% | 10% | 0% | 0% | 0% | 0% | 10% |
Respiratory, thoracic, and mediastinal disorders—nasal congestion | 80% | 20% | 0% | 0% | 0% | 0% | 20% |
Highest adverse event grade is noted for each patient. Adverse events at least possibly related to research.
Abbreviation: NC/NA, no change from baseline/no adverse event.